|
|
乌司奴单抗治疗溃疡性结肠炎的研究进展
|
Abstract:
溃疡性结肠炎(UC)是一种发病机制不明的慢性炎症性肠病，近年来生物制剂已被用于治疗UC，其疗效甚至优于传统的治疗药物。乌司奴单抗是一种抗白介素(IL)-12/23的新型生物制剂，为传统药物或其他生物制剂治疗失败的UC患者提供了新选择。本文就乌司奴单抗对UC的作用机制、临床疗效和安全性作一综述。结果表明乌司奴单抗通过与IL-12和IL-23共有的p40亚基结合，从而抑制肠道炎症，缓解UC患者的症状。并且乌司奴单抗在临床上也显示出较好的疗效与安全性，其安全性与安慰剂大致相当。由于目前暂未见其在我国用于UC，未来需进一步研究乌司奴单抗在我国UC患者中的疗效和安全性。
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown pathogenesis. In recent years, biologics have been used to treat UC with even better efficacy than traditional therapeutic drugs. Ustekinumab, a novel biologic agent against interleukin-12/23 (IL-12/23), offers a new option for UC patients who have failed treatment with conventional drugs or other biologics. This article reviews the mechanism of action, clinical efficacy and safety of ustekinumab in ulcerative colitis. The results suggest that ustekinumab alleviates the symptoms of UC patients by binding to the p40 subunit shared by IL-12 and IL-23, thereby inhibiting intestinal inflammation. And ustekinumab has also shown good efficacy and safety in clinical practice, with a safety profile roughly comparable to that of placebo. As its use for UC in China is not currently seen, further studies on the efficacy and safety of ustekinumab in Chinese patients are needed in the future.
| [1] | Ungaro, R., Mehandru, S., Allen, P.B., Peyrin-Biroulet, L. and Colombel, J. (2017) Ulcerative Colitis. The Lancet, 389, 1756-1770. https://doi.org/10.1016/s0140-6736(16)32126-2 |
| [2] | Zou, J., Liu, C., Jiang, S., Qian, D. and Duan, J. (2021) Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis. Infection and Immunity, 89, e00014-21. https://doi.org/10.1128/iai.00014-21 |
| [3] | 黄田, 李龙泉, 田珍, 等. 生物制剂治疗炎症肠病现状[J]. 中国临床药理学杂志, 2020, 36(22): 3828-3832. |
| [4] | Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S.C., Ferrante, M., Shen, B., et al. (2020) Ulcerative Colitis. Nature Reviews Disease Primers, 6, 74. https://doi.org/10.1038/s41572-020-0205-x |
| [5] | Thunberg, J., Björkqvist, O., Hedin, C.R.H., Forss, A., Söderman, C., Bergemalm, D., et al. (2022) Ustekinumab Treatment in Ulcerative Colitis: Real‐world Data from the Swedish Inflammatory Bowel Disease Quality Register. United European Gastroenterology Journal, 10, 631-639. https://doi.org/10.1002/ueg2.12275 |
| [6] | Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., et al. (2021) ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn’s and Colitis, 16, 2-17. https://doi.org/10.1093/ecco-jcc/jjab178 |
| [7] | Moschen, A.R., Tilg, H. and Raine, T. (2018) IL-12, IL-23 and IL-17 in IBD: Immunobiology and Therapeutic Targeting. Nature Reviews Gastroenterology & Hepatology, 16, 185-196. https://doi.org/10.1038/s41575-018-0084-8 |
| [8] | Fiorino, G., Allocca, M., Correale, C., Roda, G., Furfaro, F., Loy, L., et al. (2020) Positioning Ustekinumab in Moderate-to-Severe Ulcerative Colitis: New Kid on the Block. Expert Opinion on Biological Therapy, 20, 421-427. https://doi.org/10.1080/14712598.2020.1727437 |
| [9] | Kashani, A. and Schwartz, D.A. (2019) The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease. Gastroenterology & Hepatology (NY), 15, 255-265. |
| [10] | Almradi, A., Hanzel, J., Sedano, R., Parker, C.E., Feagan, B.G., Ma, C., et al. (2020) Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs, 34, 713-721. https://doi.org/10.1007/s40259-020-00451-w |
| [11] | Pugliese, D., Privitera, G., Fiorani, M., Parisio, L., Calvez, V., Papa, A., et al. (2022) Targeting IL12/23 in Ulcerative Colitis: Update on the Role of Ustekinumab. Therapeutic Advances in Gastroenterology, 15, 1-17. https://doi.org/10.1177/17562848221102283 |
| [12] | Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., Mckenzie, B., et al. (2006) IL-23 Is Essential for T Cell–mediated Colitis and Promotes Inflammation via IL-17 and Il-6. Journal of Clinical Investigation, 116, 1310-1316. https://doi.org/10.1172/jci21404 |
| [13] | Uhlig, H.H., McKenzie, B.S., Hue, S., Thompson, C., Joyce-Shaikh, B., Stepankova, R., et al. (2006) Differential Activity of IL-12 and IL-23 in Mucosal and Systemic Innate Immune Pathology. Immunity, 25, 309-318. https://doi.org/10.1016/j.immuni.2006.05.017 |
| [14] | Veisman, I. and Kopylov, U. (2022) Ustekinumab in Ulcerative Colitis-Insights from the Real‐World Data. United European Gastroenterology Journal, 10, 621-622. https://doi.org/10.1002/ueg2.12278 |
| [15] | Parigi, T.L., Iacucci, M. and Ghosh, S. (2022) Blockade of IL-23: What Is in the Pipeline? Journal of Crohn’s and Colitis, 16, ii64-ii72. https://doi.org/10.1093/ecco-jcc/jjab185 |
| [16] | Benson, J.M., Peritt, D., Scallon, B.J., Heavner, G.A., Shealy, D.J., Giles-Komar, J.M., et al. (2011) Discovery and Mechanism of Ustekinumab: A Human Monoclonal Anti-Body Targeting Interleukin-12 and Interleukin-23 for Treatment of Immune-Mediated Disorders. MAbs, 3, 535-545. https://doi.org/10.4161/mabs.3.6.17815 |
| [17] | Gisbert, J.P., Parody-Rúa, E. and Chaparro, M. (2023) Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review. Inflammatory Bowel Diseases, 30, 292-302. https://doi.org/10.1093/ibd/izac275 |
| [18] | Sands, B.E., Sandborn, W.J., Panaccione, R., O’Brien, C.D., Zhang, H., Johanns, J., et al. (2019) Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 381, 1201-1214. https://doi.org/10.1056/nejmoa1900750 |
| [19] | Abreu, M.T., Rowbotham, D.S., Danese, S., Sandborn, W.J., Miao, Y., Zhang, H., et al. (2022) Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis through 3 Years: UNIFI Long-Term Extension. Journal of Crohn’s and Colitis, 16, 1222-1234. https://doi.org/10.1093/ecco-jcc/jjac030 |
| [20] | Ochsenkühn, T., Tillack, C., Szokodi, D., Janelidze, S. and Schnitzler, F. (2020) Clinical Outcomes with Ustekinumab as Rescue Treatment in Therapy‐Refractory or Therapy‐Intolerant Ulcerative Colitis. United European Gastroenterology Journal, 8, 91-98. https://doi.org/10.1177/2050640619895361 |
| [21] | Hong, S.J., Krugliak Cleveland, N., Akiyama, S., Zullow, S., Yi, Y., Shaffer, S.R., et al. (2021) Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis from 2 Tertiary IBD Centers in the United States. Crohn’s & Colitis 360, 3, otab002. https://doi.org/10.1093/crocol/otab002 |
| [22] | Chiappetta, M.F., Viola, A., Mastronardi, M., Turchini, L., Carparelli, S., Orlando, A., et al. (2021) One-Year Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: A Multicenter Real-World Study from Italy. Expert Opinion on Biological Therapy, 21, 1483-1489. https://doi.org/10.1080/14712598.2021.1981855 |
| [23] | Chaparro, M., Garre, A., Iborra, M., Sierra-Ausín, M., Barreiro-de Acosta, M., Fernández-Clotet, A., et al. (2021) Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-World Evidence from the ENEIDA Registry. Journal of Crohn’s and Colitis, 15, 1846-1851. https://doi.org/10.1093/ecco-jcc/jjab070 |
| [24] | Aloi, M., D’Arcangelo, G., Pofi, F., Vassallo, F., Rizzo, V., Nuti, F., et al. (2013) Presenting Features and Disease Course of Pediatric Ulcerative Colitis. Journal of Crohn’s and Colitis, 7, e509-e515. https://doi.org/10.1016/j.crohns.2013.03.007 |
| [25] | Jerger, L. and Hyams, J.S. (2019) Special Considerations for Biologic Medications in Pediatric Ulcerative Colitis. Expert Opinion on Biological Therapy, 20, 429-435. https://doi.org/10.1080/14712598.2020.1685492 |
| [26] | Kakiuchi, T. and Yoshiura, M. (2022) Japanese Pediatric Patient with Moderately Active Ulcerative Colitis Successfully Treated with Ustekinumab: A Case Report. Medicine, 101, e28873. https://doi.org/10.1097/md.0000000000028873 |
| [27] | Dhaliwal, J., McKay, H.E., Deslandres, C., Debruyn, J., Wine, E., Wu, A., et al. (2021) One‐Year Outcomes with Ustekinumab Therapy in Infliximab‐Refractory Paediatric Ulcerative Colitis: A Multicentre Prospective Study. Alimentary Pharmacology & Therapeutics, 53, 1300-1308. https://doi.org/10.1111/apt.16388 |
| [28] | Cohen, S., Rolandsdotter, H., Kolho, K., Turner, D., Tzivinikos, C., Bramuzzo, M., et al. (2024) Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-Center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. Pediatric Drugs, 26, 609-617. https://doi.org/10.1007/s40272-024-00631-z |
| [29] | Kucharzik, T., Koletzko, S., Kannengießer, K. and Dignaß, A. (2020) Ulcerative Colitis—Diagnostic and Therapeutic Algorithms. Deutsches Ärzteblatt International, 117, 564-574. https://doi.org/10.3238/arztebl.2020.0564 |
| [30] | Sandborn, W.J., Feagan, B.G., Danese, S., O’Brien, C.D., Ott, E., Marano, C., et al. (2020) Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases, 27, 994-1007. https://doi.org/10.1093/ibd/izaa236 |
| [31] | Panaccione, R., Danese, S., Sandborn, W.J., O’Brien, C.D., Zhou, Y., Zhang, H., et al. (2020) Ustekinumab Is Effective and Safe for Ulcerative Colitis through 2 Years of Maintenance Therapy. Alimentary Pharmacology & Therapeutics, 52, 1658-1675. https://doi.org/10.1111/apt.16119 |
| [32] | Fumery, M., Filippi, J., Abitbol, V., Biron, A., Laharie, D., Serrero, M., et al. (2021) Effectiveness and Safety of Ustekinumab Maintenance Therapy in 103 Patients with Ulcerative Colitis: A GETAID Cohort Study. Alimentary Pharmacology & Therapeutics, 54, 944-951. https://doi.org/10.1111/apt.16544 |
| [33] | Rosh, J.R., Turner, D., Griffiths, A., Cohen, S.A., Jacobstein, D., Adedokun, O.J., et al. (2021) Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UNISTAR, a Phase 1 Study. Journal of Crohn’s and Colitis, 15, 1931-1942. https://doi.org/10.1093/ecco-jcc/jjab089 |
| [34] | Laube, R., Paramsothy, S. and Leong, R.W. (2021) Use of Medications during Pregnancy and Breastfeeding for Crohn’s Disease and Ulcerative Colitis. Expert Opinion on Drug Safety, 20, 275-292. https://doi.org/10.1080/14740338.2021.1873948 |
| [35] | Saito, J., Kaneko, K., Kawasaki, H., Hayakawa, T., Yakuwa, N., Suzuki, T., et al. (2022) Ustekinumab during Pregnancy and Lactation: Drug Levels in Maternal Serum, Cord Blood, Breast Milk, and Infant Serum. Journal of Pharmaceutical Health Care and Sciences, 8, Article No. 18. https://doi.org/10.1186/s40780-022-00249-8 |
| [36] | Mahadevan, U., Robinson, C., Bernasko, N., Boland, B., Chambers, C., Dubinsky, M., et al. (2019) Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology, 156, 1508-1524. https://doi.org/10.1053/j.gastro.2018.12.022 |
| [37] | Lasa, J.S., Olivera, P.A., Danese, S. and Peyrin-Biroulet, L. (2022) Efficacy and Safety of Biologics and Small Molecule Drugs for Patients with Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. The Lancet Gastroenterology & Hepatology, 7, 161-170. https://doi.org/10.1016/s2468-1253(21)00377-0 |
| [38] | Chae, K., Seo, Y.S., Yu, Y.M., Chang, M.J. and Choi, J. (2023) An Indirect Comparison of Efficacy Including Histologic Assessment and Safety in Biologic Therapy in Ulcerative Colitis: Systemic Review and Network Meta-Analysis. PLOS ONE, 18, e0293655. https://doi.org/10.1371/journal.pone.0293655 |
| [39] | Singh, S., Murad, M.H., Fumery, M., Dulai, P.S. and Sandborn, W.J. (2020) First-and Second-Line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clinical Gastroenterology and Hepatology, 18, 2179-2191.e6. https://doi.org/10.1016/j.cgh.2020.01.008 |
| [40] | Iwakura, Y. and Ikblemae, H. (2006) The IL-23/IL-17 Axis in Inflammation. Journal of Clinical Investigation, 116, 1218-1222. https://doi.org/10.1172/jci28508 |
| [41] | Noviello, D., Mager, R., Roda, G., Borroni, R.G., Fiorino, G. and Vetrano, S. (2021) The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Frontiers in Immunology, 12, Article No. 1735. https://doi.org/10.3389/fimmu.2021.611256 |
| [42] | Sandborn, W.J., Ferrante, M., Bhandari, B.R., Berliba, E., Feagan, B.G., Hibi, T., et al. (2020) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Ulcerative Colitis. Gastroenterology, 158, 537-549.e10. https://doi.org/10.1053/j.gastro.2019.08.043 |
